Em recrutamento
FASE
Número Europeu 2023-508219-21-00
JZP598-302
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
Detalhes
Destaques